Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.

Cancer letters - 28 Jul 2012

Shojaei Farbod

Abstract excerpt

It has been nearly 9years since the FDA (Food and Drug Administration) approved the first anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other angiogenic inhibitors have since been approved or are in different stages of clinical trials. However, continued clinical and preclinical investigations have identified major drawbacks associated with the application of this class of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Biomarkers, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Stromal Cells

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 22425960
DOI: 10.1016/j.canlet.2012.03.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.PMID 22425960Read ↗

Tumor angiogenesis: causes, consequences, challenges and opportunitiesSemantic proximity Read ↗

Biomarkers of Angiogenesis in Colorectal CancerSemantic proximity Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Semantic proximity Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Semantic proximity Read ↗

Targeted treatments in colorectal cancer: state of the art and future perspectives.Semantic proximity Read ↗

Angiogenesis: A Target for Cancer TherapySemantic proximity Read ↗

Inducing Angiogenesis, A Key Step in Cancer Vascularization, and Treatment ApproachesSemantic proximity Read ↗

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].Semantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.